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HIV-associated nephropathy (HIVAN) is a clinicopathologic entity character-
ized by heavy proteinuria, absence ofedema and an irreversible decline in renal
function. Findings on renal biopsy include: collapsed glomerular capillaries;
visceral glomerular epitheliosis; microcystic tubules; mesangial prominence;
and endothelial tubuloreticular inclusions. Early in theAIDS epidemic, HIVAN
was the predominant glomerular lesion observed in HIV-infected patients. It is
being increasingly recognized, especially in Caucasian populations, that a vari-
ety of immune complex-mediated lesions such as membranoproliferative
glomerulonephritis, proliferative glomerulonephritis and IgA nephropathy are
associated with HIV infection.
In this review we present two cases: one patient whose first presentation of
AIDS was end-stage renal disease, who on biopsy was found to have HIVAN,
and the second, who was infected with HIV, and on biopsy was found to have
hepatitis C-related hepatitis C related membranoproliferative glomerulonephri-
tis. We also review the current literature on HIVAN and HIV-associated immune
complex diseases (HIVICDs). Each case illustrates an important clinical point.
The first that renal disease can be the first manifestation of HIV infection and
the second that HIV-infected patients may develop immune complex related
renal diseases, some of which may be potentially treatable.
INTRODUCTION
The association of HIV infection and renal disease first emerged in the mid-1980s
with the initial description of HIV-associated nephropathy (HIVAN)b [1]. After a brief
debate on whether this syndrome was related to heroin nephropathy, clinical experience
subsequently revealed that HIVAN was indeed a distinct clinicopathologic entity. HIVAN
affects predominantly young black males, including those with risk factors for HIV infec-
tion other than intravenous drug abuse, and is characterized by heavy proteinuria and a
rapid, irreversible decline in renal function. Pathologic findings include: collapsed
glomerular capillaries; visceral glomerular epitheliosis; microcystic tubules containing
proteinaceous casts; mesangial prominence; and endothelial tubuloreticular inclusions.
Biopsy series have subsequently expanded the spectrum of glomerular lesions in
HIV-infected patients to include immune complex disorders such as membranoprolifera-
tive glomerulonephritis [2], proliferative glomerulonephritis [3] and IgA nephropathy [4]
a To whom allcorrespondence should be addressed: Robert F. Reilly, M.D., Section ofNephrology-
11IF, Department of Medicine, Denver VA Medical Center, 1055 Clermont Street., Denver, CO.
Tel.: 303-399-8020, ext. 3101; Fax: 303-393-461 1.
bAbbreviations: AIDS, acquired immunodeficiency syndrome; CAPD, continuous ambulatory peri-
toneal dialysis; EEG, electroencephalogram; ESRD, end stage renal disease; FSGS, focal segmental
glomerulosclerosis; HIV, human immunodeficiency virus; HIVAN, human immunodeficiency virus-
associated nephropathy; HIVICD, human immunodeficiency virus-associated immune complex dis-
eases; TGF, transforming growth factor.
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for which HIV likely plays an important pathogenetic role. HIV-associated immune com-
plex diseases (HIVICDs) share common clinical manifestations with their counterparts in
non-HIV-infected patients. However, as clinical syndromes related to HIV infection they
have not been as widely characterized or speculated to have the same epidemiological
impact as HIVAN.
This article will present two cases that demonstrate the importance of a diagnostic
renal biopsy in HIV-associated renal disease and review the clinical presentation, pathol-
ogy, pathogenesis andpotential therapies ofHIVAN, as well as emerging concepts regard-
ing the recently recognized HIVICDs.
CASES
Case 1: A 35 year old black male with a history ofchronic alcohol abuse, whose last
stated drink was three weeks prior to admission, presented to the emergency department
after two generalized tonic-clonic seizures. He had noted increased urination, occasional
pruritus and a 9 kg weight loss over the previous year. There was no significant past med-
ical history, and he was on no medication. He denied intravenous drug use, but admitted
to having multiple heterosexual partners.
On physical examination, he was alert, in no distress and afebrile. Blood pressure was
150/90 mm Hg, and the pulse was 108. Examination ofthe head and neck was unremark-
able. No thrush was noted. Cardiac, chest, and abdominal exam were normal. There was
no peripheral edema. Neurological exam was unremarkable.
Laboratory data: BUN, 116 mg/dl, creatinine, 8.6 mg/dl, electrolytes within normal
limits, Hct, 25.6 percent and creatine kinase, 527 U/l. Urinalysis revealed 3+ protein and
an inactive sediment. Renal ultrasound examination showed no hydronephrosis, and the
kidneys were 11 cm bilaterally with increased echogenicity. Computerized tomography of




Figure 1. Light micrograph demonstrating Figure 2. Light micrograph demonstrating
several characteristics ofHIVAN including: interstitial nephritis and scarring.
diffuse tubular dilatation with microcysts; (Magnification: 75X).
glomerular collapse and sclerosis; and a
pseudocrescent (shown at the arrowhead).
(Magnification: 75X).
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Figure 3. Electron micrograph of a capillary loop showing widespread effacement ofvisceral
epithelial foot processes (shown at the arrowhead). (Magnification: 2,550X).
A light microscopic section of the renal cortex is shown in Figure 1. There is diffuse
tubular dilatation with microcystic tubules containing large proteinaceous casts. The inter-
stitium is widened, and a patchy cellular infiltrate can be seen. The glomerulus at the bot-
tom of the figure is collapsed, and a second glomerulus shows evidence of sclerosis and
capillary loop collapse, as well as a pallisading of visceral epithelial cells that form a
pseudocrescent (shown at the arrowhead). A prominent area of interstitial scarring and
focal interstitial nephritis is visualized in Figure 2. Widespread effacement of visceral
epithelial foot processes was seen on electron microscopy (arrowhead Figure 3). This con-
stellation offindings was strongly suggestive of HIVAN, and HIV serology subsequently
returned positive.
Case 2: A 45 year old black male, known to be HIV positive since 1985, was admit-
ted to the hospital with increasing abdominal girth and leg edema. The patient had a
known history of intravenous drug abuse and was continuing to use three bags of heroin
daily. He had no previous history ofopportunistic infection. Past medical history was sig-
nificant for hypertension, endocarditis, aseptic meningitis and microscopic hematuria. He
was on no medication. In 1992, a 24-hour urine showed 1.4 grams ofprotein.
On physical examination he was in no distress and appeared chronically ill. The tem-
perature was normal, with a blood pressure of 200/100 mmHg, and a pulse of 80. The
remainder of the physical examination was remarkable only for ascites and peripheral
edema to the mid-thigh.
Laboratory data: BUN, 32 mg/dl, creatinine, 1.6 mg/dl, albumin, 1.5 g/dl, total pro-
tein, 8.1 g/dl. Urinalysis revealed 3+ protein, large blood, 2-5 WBC/HPF and 11-20
RBC/HPF. Twenty-four-hr urine studies revealed a creatinine clearance of 34.7 ml/min,
and 2.34 g protein. Renal ultrasound examination revealed moderate ascites and enlarged
echogenic kidneys. A renal biopsy was performed.
A light microscopic section ofthe kidney cortex is shown in Figure 4. Two glomeruli
are seen, and each shows evidence ofhypercellularity and lobular accentuation. The inter-
stitium is also widened with a marked increase in cellularity. Electron microscopy
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Figure 4. Light micrograph
showing a hypercellular glo-
merulus with evidence oflob-
ular accentuation. (Magnifica-
tion-180X)
Figure 5. Electron micrograph showing diffuse subendothelial deposits (shown at the arrow-
head). (Magnification 7,950X).
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Figure 6. Electron micrograph showing numerous subendothelial deposits (shown at the
arrowhead). (Magnification: 1O,05OX).
revealed both diffuse subendothelial deposits (arrowhead in Figure 5), as well as numer-
ous large subepithelial deposits (arrowhead in Figure 6). There was prominent mesan-
gialization of the glomerular basement membrane seen in additional sections, along with
focal glomerular intracapillary deposits suggestive of cryoglobulins (not shown). These
findings were felt to be most compatible with membranoproliferative glomerulonephritis
secondary to hepatitis C. A test for hepatitis C antibody was positive.
Each of the above cases illustrates an important point regarding HIV-associated
glomerular disease. The first case shows that renal involvement may be the first manifes-
tation ofHIV infection, and the second case demonstrates that patients infected with HIV
can develop potentially treatable renal diseases that are not unique to HIV infection.
Consistent with the classic clinical picture ofHIVAN, the first patient presented with
azotemia, proteinuria, the absence of edema and hypertension, and enlarged echogenic
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kidneys. However, the second patient had an indolent course of moderate renal insuffi-
ciency, proteinuria, edema, and hypertension, inconsistent with the usual presentation of
HIVAN. Renal biopsy established the diagnosis of membranoproliferative glomeru-
lonephritis secondary to hepatitis C and the patient was subsequently treated with a-inter-
feron.
In this manuscript, we will review the spectrum ofglomerular lesions that have been
associated with HIV infection. These disorders will be divided into two major categories:
HIV-associated nephropathy (HIVAN) and HIV-associated immune complex diseases
(HIVICDs). With respect to HIVAN we will discuss its epidemiology and history, clinical
presentation, pathologic features and emerging concepts regarding its pathogenesis and
treatment. We will also describe several recent studies that suggest that glomerular disor-
ders classically associated with immune-complex deposition may be associated with HIV
infection (HIVICDs) and close by discussing what is known about hepatitis C-related
renal disease in HIV-positive patients.
HIVAN
Epidemiology and history
Early biopsy series from NewYork City [1, 2] and Miami [5] showed that focal seg-
mental glomerulosclerosis (FSGS) was the principal pathologic lesion in patients with
AIDS and nephrotic range proteinuria. Rao et al. [6] reported that among a series of 750
patients treated with AIDS at two NewYork City hospitals, 55 had azotemia and protein-
uria (43 ofthese developed irreversible uremia). Ofthis group 30 had either a renal biop-
sy orautopsy. Pathologic examination showed FSGS in 27 patients and mesangial changes
in three. Risk factors for HIV infection included: intravenous drug use, 55 percent; homo-
sexual contact, 9 percent; and unknown, 11 percent. Five patients had a history of both
intravenous drug use and homosexual contact. All 55 patients were black, and only six
were women.
This finding remained controversial in view of the fact that early studies from San
Francisco andWashington, D.C. failed to demonstrate a clinical syndrome ofAIDS-asso-
ciated nephropathy [7, 8]. The controversy centered on the premise that since FSGS was
characteristic ofheroin nephropathy, and that intravenous drug use is a common risk fac-
tor forAIDS, that the nephropathy seen in AIDS patients might be related more to intra-
venous drug use than to HIV infection. In retrospect, this lack of early geographic con-
cordance was probably due to differences in the racial makeup of patient populations, in
that the San Francisco and Washington, D.C. series were made up primarily of white
homosexuals [9]. Subsequently, as the AIDS epidemic progressed it was evident that
HIVAN was indeed a distinct clinicopathologic entity.
Current evidence supports race as a significant co-factor in the development of
HIVAN as it is for many renal disorders [10]. In the United States, 90 percent of all
patients with HIVAN are black [11], and the gender breakdown is similar to that of HIV
infection. At the University ofMiami/Jackson Medical Center, 88 percent ofpatients with
HIVAN are black, while the ratio of white to black patients at this center is 2:1 [12]. A
European series involving 203 patients, all of whom were white, failed to identify any
biopsy documented cases ofHIVAN [13]. The classic clinical andpathologic presentation
ofHIVAN has been confirmed in patients with every known risk factor for HIV transmis-
sion [14]. Overall in this country, 30-50 percent of cases have intravenous drug use as a
risk factor.
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Clinical presentation
Patients generally present with varying degrees of proteinuria and/or renal insuffi-
ciency. More than half are at an early stage of HIV infection. It is not uncommon for
patients previously undiagnosed with HIV to present with end-stage renal failure sec-
ondary to HIV-associated glomerulosclerosis as seen in our first case [15]. Typically, the
serum creatinine is 2 mg/dl or higher, and the serum albumin is low. Ten to 20 percent may
have normal renal function. The progression to nephrotic-range proteinuria occurs over
several weeks to months, although some patients have a more indolent time course [16].
Despite nephrotic-range proteinuria and hypoalbuminemia, edema is conspicuously
absent. Several potential explanations have been offered including: intravascular volume
depletion due to chronic diarrhea and malnutrition/malabsorbtion; that the excess globu-
lins due to the polyclonal gammopathy of HIV infection may offset the loss of oncotic
pressure from hypoalbuminemia; and salt wasting.
After the onset of nephrotic-range proteinuria, the progression to end-stage renal dis-
ease (ESRD) is characteristically rapid [16, 17]. Patients often remain normotensive
throughout unless underlying essential hypertension is present, in which case the pro-
gression to ESRD is even more rapid. Langs et al. reported 15 patients with HIVAN with-
out edema or hypertension (except one that previously had essential hypertension) [17].
Thirteen progressed to ESRD: eight within four months; four within four-1O months; and
one within 27 months. Other larger series have shown similar results. Ultrasound studies
in HIVAN reveal enlarged echogenic kidneys that remain large despite the progression to
ESRD [18].
Pathology
Grossly the kidneys are enlarged bilaterally. Occasional cysts are visible, which rep-
resent massively dilated tubules. On light microscopy there are abnormalities involving
the glomeruli, tubules and interstitium [19]. These include: collapse ofthe glomerular cap-
illary; mesangial prominence; visceral epithelial cell swelling and vacuolization; intersti-
tial fibrosis and edema; cystic tubular degeneration and necrosis with the tubular lumen
filled with eosinophilic proteinaceous material (microcysts) [20]. Immunofluorescence
analysis shows deposition of immunoglobulins, chiefly IgM and complement, in areas of
glomerular sclerosis. Tubular casts contain immunoglobulins, complement, light chains,
albumin, and fibrin but not Tamm-Horsfall protein, which is frequently found in adjacent
nondilated tubules [19]. Electron microscopy reveals widespread effacement of visceral
epithelial foot processes. Characteristic tubuloreticular inclusion bodies are found in tubu-
lar, interstitial, endothelial and glomerular epithelial cells, as well as in interstitial leuko-
cytes [21]. Other ultrastructural abnormalities include: granular degeneration of the
nuclear chromatin; and increased numbers of nuclear bodies [20, 21].
Pathogenesis
Early investigations centered around an attempt to identify an infectious agent, and at
various points, cytomegalovirus and Mycoplasma fermentans were invoked and subse-
quently dismissed [22]. Renal ischemia has been suggested as an explanation for the tubu-
lar cell necrosis and glomerular collapse; however, this would not explain the proteinuria
nor the structural abnormalities in glomerular visceral epithelial cells [17]. The strikingly
dilated tubules occluded with proteinaceous material has led to tubular obstruction being
postulated as another possible mechanism in the rapid progression of the nephropathy
[17].
The presence of HIV genome in renal cells has been demonstrated in two studies.
Cohen et al. employed immunohistochemistry using an antibody to p24 and in situ
hybridization to show the presence of HIV genome in many glomerular and tubular
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epithelial cells in patients with both HIVAN and HIVICDs [23]. Kimmel et al. evaluated
22 biopsy specimens from HIV-positive patients with renal disease using the polymerase
chain reaction ofmicrodissected tissue with primers and probes to the gag gene [24]. HIV
genome was demonstrated in glomeruli, tubules, interstitial cells and infiltrating inflam-
matory cells, but not interstitial cells. HIV DNA was detected in 21 of 22 specimens.
Control specimens from HIV-infected patients without clinical evidence of renal disease
were positive as well. This study includedpatients with both HIVAN and HIVICDs. These
data suggest that the presence of HIV genomic material may be necessary, but not suffi-
cient to produce clinically evident disease. To date, HIV RNAs or cDNAs have not been
identified in kidney.
Cytokines and growth factors are important agents in the pathogenesis ofmany renal
diseases [25]. Several studies involving animal models have suggested thatTGF-P plays
arole in the pathogenesis ofglomerulosclerosis [26]. HIV-infected human mesangial cells
increase expression of HIV genes in response to exposure to TGF-,B in vitro [27]. AIDS
patients are known to have increased circulating levels of this growth factor, and patients
with HIVAN have increased expression of TGF-1 in biopsy specimens [27]. It has been
suggested that TGF-3 might induce increased matrix production by either mesangial or
other cells, and that this could then result in decreased renal function.
Mice transgenic for a noninfectious HIV provirus gene develop renal disease charac-
terized by FSGS, proteinuria, interstitial nephritis and tubular cysts [28]. These mice
express HIV-specific transcripts in several tissues including the kidney, suggesting that
certain viral gene products, but not the virus itself, may exert a pathologic effect. Further
studies employing this model have shown a potential pathogenetic role for cytokines
including TGF-3 and basic fibroblast growth factor [29].
Treatment
There is no proven effective treatment for HIVAN. In a small study involving four
patients with biopsy-proven HIVAN and advanced renal insufficiency corticosteroids
were administered for two-six weeks (1 mg/kg/day) [30]. Although mean plasma creati-
nine fell from 9.1 to 3.3 mg/dl, there was no change in urinary protein excretion. Two
patients suffered serious adverse effects (Mycobacterium avium-complex infection and
steroid-induced psychosis). The improvement in renal function without a change in pro-
teinuria may be more indicative of a reversal ofan interstitial nephritis than a glomerular
lesion.
Experience with cyclosporine is limited to three pediatric patients with HIVAN and
nephrotic syndrome treated for very short periods oftime (three, six and 12 months) [31].
The nephrotic syndrome resolved in all three cases.
Three recent studies have suggested that there may be a role for zidovudine in the
treatment ofpatients with HIVAN. In a retrospective study six patients with biopsy-proven
HIVAN were administered 300 to 800 mg/day of zidovudine [32]. In two patients with
advanced renal disease, there was no benefit. In four patients with less advanced disease
(serum creatinines ranging from 1.2 to 5.2 mg/dl), there was a delay in the need for chron-
ic dialysis for up to 33 months. In the second study, 23 patients with a mean serum crea-
tinine of 1.2 mg/dl were treated prospectively with 400 to 800 mg/day ofzidovudine [33].
Of the eight patients who stopped taking zidovudine, all progressed to ESRD within a
mean ofeight weeks. In the 15 patients who were zidovudine compliant, none developed
ESRD or a progression of azotemia. However, only five members of the study group had
undergone renal biopsy (all had HIVAN), and only 14 of the 23 had proteinuria. In the
third study, 43 of54 patients with 2+ or greater proteinuria were given zidovudine and 11
were not [34]. Six patients who were already azotemic before zidovudine administration
went on to develop ESRD. Of the nonazotemic patients, 40 percent that did not receive
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zidovudine progressed to mild azotemia (four of 10), while only five of 37 receiving the
drug progressed during a two-year period.
Captopril was recently shown to increase renal survival in small groups of patients
with biopsy proven HIVAN in two studies. In the first nine patients were treated with cap-
topril, and an additional nine patients served as controls [35]. Subjects in each group were
matched for age, race, gender and level ofserum creatinine. At the onset oftreatment, the
mean serum creatinine was 3.4 ± 0.7 in the captopril group and 3.7 ± 0.5 in the control
group. Renal survival was defined as the time from renal biopsy to the time of onset of
treatment for ESRD. Mean renal survival was 156 ± 71 days in the captopril group vs. 37
± 5 days in the control group (p < .002). In the second study, three patients with biopsy-
proven HIVAN were treated with fosinopril (10 mg/day), and compared to four controls
matched for age, sex, race, baseline creatinine and 24-hr urinary protein excretion [36].
After six months, the treated patients had a lower serum creatinine (1.5 mg/dl ± 0.09 vs.
5.4 mg/dl ± 0.14) and lower 24-hr protein excretion (1.5 ± 0.14 g vs. 8.5 ± 0.72 g) com-
pared to the control group.
It was noted early in the epidemic that patients maintained on hemodialysis experi-
enced a wasting syndrome leading to death after about six months [37]. Although survival
is generally short once ESRD develops, itmay exceed one to two years in those at an early
stage of illness [38]. In a recent report of 61 patients treated at Wayne State, the overall
survival at one, two and three years was 50 percent, 30 percent and 10 percent, respec-
tively. Mortality was related to infectious complications and the number ofAIDS-related
organ involvement [39]. There appears to be no difference in mortality between continu-
ous ambulatory peritoneal dialysis (CAPD) and hemodialysis, and the peritonitis rate of
HIV-infected patients was similar to that of non-HIV infected patients on CAPD in one
study [40]. Another study showed that the peritonitis rate in HIV-infected patients was 2.6
times higher than in non-HIV infected patients [41]. However, peritonitis related compli-
cations rarely resulted in the discontinuation ofCAPD.
Most centers will not transplant HIV-positive patients. Howevler, before systematic
screening of recipients and donors began in 1985, whole organ transplants were inadver-
tently carried out on HIV carriers. In one study, 25 HIV-positive patients received whole-
organ transplants, five of whom were kidney transplants [42]. Mean follow-up in these
patients was 3.4 years, and two patients have survived for more than five years. HIV-pos-
itive whole-organ transplant recipients appear to have a shorter time to the onset ofAIDS
than control patients who have acquired the virus from the transfusion ofblood products.
However, in this study, AIDS-defining opportunistic infections were assumed to be the
result of HIV infection rather than secondary to transplant-related immunosuppression.
HIV-ASSOCIATED IMMUNE COMPLEX DISEASES (HIVICDS)
Background
Several biopsy series now support the contention that HIVAN is notthe only glomeru-
lar lesion seen in HIV-infected patients. The histopathology in 40 patients with HIV infec-
tion and clinical evidence of renal disease undergoing kidney biopsy at the George
Washington University Medical Center in Washington, D.C. since 1986 is shown below in
Table 1.
Further studies were carried out on four of the above patients with proliferative
glomerulonephritis [43]. All were black, and had renal insufficiency and proteinuria.
Circulating immune complexes and HIV-reactive antibodies were found in the sera of all
four patients. Eluted samples from biopsy specimens were analyzed and demonstrated com-
plexes ofantibody with various HIV antigens, uncomplexed HIV antigens andcomplement.
169Wrone et al.: Glomerular lesions in HIV-infectedpatients
Table 1. Histopathology ofHIV-infected patients at George Washington University Hospital.
Pathologic lesion Number of pts. (percent)
Focal glomerulosclerosis (HIVAN) 20 (50)
Glomerulonephritis 14 (35)
Focal proliferative glomerulonephritis 6
IgA nephropathy 2
Membranous nephropathy 2 (5)
Acute tubular necrosis 2 (5)
Diabetic nephropathy 2 (5)
In addition, eluted antibodies were shown to react with HIV antigens from the isolated cir-
culating immune complexes.
In Europe, among whites infected with HIV, a variety ofglomerular lesions have been
reported, however, HIVAN is rare. In Italy, Casanova et al. reviewed 26 renal biopsy spec-
imens from HIV-infected patients with suspected glomerular involvement [44]. All
patients were Italian, and 19 ofthe 26 were intravenous drug abusers. Glomerular pathol-
ogy included: minimal change disease (two patients); mesangial proliferative glomeru-
lonephritis (four patients); post-infectious glomerulonephritis (six patients); membra-
noproliferative glomerulonephritis (one patient); membranous glomerulonephritis (three
patients); IgA nephropathy (fourpatients); mixed membranous and proliferative glomeru-
lonephritis (three patients); diffuse proliferative glomerulonephritis with subendothelial
deposits and intraluminal thrombi (two patients); proliferative glomerulonephritis with
subepithelial and subendothelial deposits (one patient). Tubuloreticular inclusions were
seen in all patients. There were no cases ofHIVAN. Nochy et al. studied 60 patients from
Paris area hospitals; 29 patients were black and 31 were white [45]. Only three of the 31
white patients were found to have HIVAN (the majority had glomerulonephritis), while 23
of 29 black patients had HIVAN, and only 21 percent of black patients had glomeru-
lonephritis.
IgA nephropathy
While HIV-infected patients may develop diseases unrelated and coincidental to HIV
infection, evidence is accumulating for a unique form ofIgA nephropathy stemming from
an HIV-related immunologic process. Other possibly HIV-related immune complex dis-
eases such as membranous glomerulonephritis, membranoproliferative glomerulonephri-
tis and acute proliferative glomerulonephritis have been described. However, the role of
HIV infection in their pathogenesis has yet to be determined.
Several mechanisms have been proposed as possible explanations for an increased
susceptibility of HIV-infected patients to IgA nephropathy. HIV-infected patients com-
monly have increased levels of circulating IgA (primarily directed at the HIV envelope
glycoproteins gpl60, gpl20 and gp4l), as well as circulating immune complexes con-
taining IgA and IgA rheumatoid factors, suggestive of abnormalities of IgA regulation
[46]. Race and genetic factors have also been invoked since all of the HIV-infected
patients with IgA nephropathy reported to date have been white.
Katz et al. studied four white HIV-positive patients with IgA nephropathy on biopsy
[47]. Elevated serum levels ofIgA, as well as IgA immune complexes and rheumatoid fac-
tors were found. IgA antibodies to multiple HIV antigens were detected by Western blot
in serum. However, the authors were unable to demonstrate HIV antigens in the biopsy
specimens using either monoclonal antibodies or in situ hybridization.
Kimmel et al. studied two HIV-positive patients with IgA nephropathy [48].
Circulating immune complexes were isolated (composed of IgA and IgG in one patient,
170Wrone et al.: Glomerular lesions in HIV-infectedpatients 171
and IgA and IgM in the other) as well as IgA idiotypic antibodies (antibodies that inhib-
ited the binding of HIV antigen to anti-HIV antibodies). Identical material was recovered
from the renal tissues of one ofthe patients by elution.
A proposed mechanism for the development ofimmune complex-mediated renal dis-
ease in HIV-infected patients is the deposition ofcirculating immune complexes or poly-
clonal B-cell activation against an HIV-related antigen in renal tissue. HIV DNA has been
demonstrated in renal tissue, and HIV p24 antigen has been shown in biopsy specimens
suggesting that there may be cellular incorporation ofHIV genome products and the sub-
sequent deposition ofantibody or circulating immune complexes. Interstitial inflammato-
ry infiltrates are present in both HIVICDs and HIVAN. These cells are perhaps important
in the pathogenesis of both entities due to their elaboration of various cytokines. Bodi et
al. characterized the interstitial cell population in HIVAN and HIVICDs and in HIV-neg-
ative FSGS control patients [49]. He found that in HIVAN a greaterproportion ofthe cells
were macrophages and a lesser proportion B-cells as compared to HIVICDs.
HEPATITIS C, MEMBRANOPROLIFERATIVE
GLOMERULONEPHRITIS AND HIV INFECTION
As in case 2, HIV-positive patients are susceptible to other renal diseases including
those that respond to specific treatment, making kidney biopsy a potentially important
diagnostic tool. Hepatitis C virus infection has been associated with immunologically-
mediated renal disease. Johnson et al. reported eight patients with chronic hepatitis C
infection and membranoproliferative glomerulonephritis [50]. Four ofthese patients were
treated with a-interferon for periods of 2-12 months with a decrease in proteinuria. Two
small series consisting of eight and 12 HIV-positive patients, respectively, have reported
using a-interferon for three-six months for the treatment of chronic hepatitis with no dif-
ferences noted in the response to, ortolerance of, therapy when compared to patients with-
out evidence ofHIV infection [51, 52]. Taken together, these studies suggest that a-inter-
feron may be useful for the treatment ofmembranoproliferative glomerulonephritis in the
HIV-positive population. However, it should be noted that long-term, high-dose a-inter-
feron therapy has been associated with the development of membranoproliferative
glomerulonephritis in at least one HIV-positive patient [53]. In this case report antigen-
antibody complexes containing a-interferon were isolated from both the circulation and
renal tissue.
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